| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6109385 | Journal of Hepatology | 2008 | 9 Pages |
Abstract
Bevacizumab and rapamycin, which are both clinically approved drugs, may represent a novel molecularly-targeted combination treatment for hepatocellular carcinoma.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Hung Huynh, Pierce K.H. Chow, Nallasivam Palanisamy, Manuel Salto-Tellez, Boon Cher Goh, Chi Kuen Lee, Anaji Somani, How Sung Lee, Ramnarayanan Kalpana, Kun Yu, Puay Hoon Tan, Jeanie Wu, Richie Soong, Ming Hui Lee, Henley Hor, Khee Chee Soo,